Myeloid leukaemia (acute and chronic) 1969–2001 in a combined population based cohort of 47 679 Swedish patients with inflammatory bowel disease
| Ulcerative colitis | Crohn’s disease | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| O | E | SIR (95% CI) | RR | p Value | O | E | SIR (95% CI) | RR | p Value | |
| *–1979 and 1980–1989 were combined into one category. | ||||||||||
| First year of follow up excluded. | ||||||||||
| Observed (O) and expected (E) number of myeloid leukaemia, standardised incidence ratio (SIR) with 95% confidence intervals (95% CI), and multivariate relative risks (RR) from models including all parameters in table (“ref” denotes reference category). | ||||||||||
| p values refer to type 3 tests. | ||||||||||
| Overall | 32 | 18 | 1.8 (1.2–2.6) | – | – | 13 | 11 | 1.2 (0.6–2.0) | – | – |
| Sex | ||||||||||
| Male | 23 | 10 | 2.2 (1.4–3.3) | 1 (ref.) | 0.13 | 5 | 5.6 | 0.9 (0.3–2.1) | 1 (ref.) | 0.34 |
| Female | 9 | 7.3 | 1 (0.6–2.3) | 0.6 (0.3–1.2) | 8 | 5.3 | 1.5 (0.7–3.0) | 1.7 (0.6–5.2) | ||
| Cohort of origin | ||||||||||
| Any regional cohort | 13 | 5.0 | 2.6 (1.4–4.5) | 2.2 (0.9–5.0) | 0.07 | 3 | 3.2 | 0.9 (0.2–2.8) | 0.9 (0.2–3.6) | 1 |
| Inpatient register only | 19 | 13 | 1.5 (0.9–2.3) | 1 (ref.) | 10 | 7.8 | 1.3 (0.6–2.4) | 1 (ref.) | ||
| Calendar period at follow up | ||||||||||
| –1979 | 0 | 1.5 | 0.0 (0.0–2.4) | 1 | 0.9 | 1.1 (0.0–6.4) | 1 (ref.) | 0.46 | ||
| 1980–1989 | 9 | 4.9 | 1.8 (0.8–3.5) | 1 (ref.)* | 0.15 | 4 | 2.9 | 1.4 (0.4–3.6) | 1.2 (0.1–11) | |
| 1990–2001 | 23 | 11 | 2.1 (1.3–3.1) | 1.8 (0.8–4.3) | 8 | 7.2 | 1.1 (0.5–2.2) | 1.1 (0.1–9.6) | ||
| Time of follow up (y) | ||||||||||
| 1–5 | 6 | 5.6 | 1.1 (0.4–2.3) | 0.9 (0.3–2.5) | 0.19 | 4 | 3.2 | 1.2 (0.3–3.2) | 1.5 (0.3–) | 0.47 |
| 6–10 | 11 | 4.1 | 2.7 (1.3–4.8) | 1.9 (0.8–4.6) | 5 | 2.6 | 1.9 (0.6–4.5) | 2.4 (0.6–9.5) | ||
| ⩾11 | 15 | 7.9 | 1.9 (1.1–3.1) | 1 (ref.) | 4 | 5.1 | 0.8 (0.2–2.0) | 1 (ref.) | ||